Latest eBooks

Dysfunctional metabolism is associated with a growing number of different disease states. The ability to examine the genes, proteins and pathways that modulate energy metabolism is therefore a promising new avenue for drug discovery.

Working at the correct safety level depending on the given organism or toxin you are working with in a biosafety lab is essential to minimize the risk of laboratory-associated infections and contamination of the environment. Each biosafety level has its associated risk assessments, microbiological practices and containment procedures for you to follow.

Greater appreciation for the complex and dynamic connections between metabolic poise and immune cell function enables researchers to monitor and control how metabolic reprogramming and microenvironmental signals affect the function, fate and fitness of immune cells.

Download this eBook to discover new analytical solutions to accelerate AAV-based gene therapy.

Download this eBook to explore how synthetic biology is being utilized in the development of cell and gene therapies, cancer therapeutics and improved food and agriculture production processes.

Cell-based assays offer extensive advantages across multiple fields of research, advantages that can be maximised by the specialised features and high throughput capabilities of microplate readers.

In the “Quality by Design” approach for monoclonal antibody (mAb)-based therapeutics development, stability characterization—the probability of a protein unfolding—is performed to ensure that structure and function are preserved throughout development and manufacturing.

Download this eBook to discover how advances in different technologies and techniques continue to expand the possibilities of personalized medicine.

Download this eBook to explore recent advances in proteomics technologies, key applications including vaccine design and drug development, and the problem of understudied proteins.

Artificial intelligence (AI) is changing the game for drug discovery and repurposing. There are currently more than 100 drugs in the AI drug discovery pipeline and numerous more that are making their way to clinical trials in a matter of years—instead of decades.